Superbugs: Should antimicrobial resistance be included as a cost in economic evaluation?
Author
Abstract
Suggested Citation
DOI: 10.1002/(SICI)1099-1050(199605)5:33.0.CO;2-S
Download full text from publisher
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Klaus Kaier & S. Moog, 2012. "Economic Consequences of the Demography of MRSA Patients and the Impact of Broad-Spectrum Antimicrobials," Applied Health Economics and Health Policy, Springer, vol. 10(4), pages 227-234, July.
- Lina Maria Ellegård & Jens Dietrichson & Anders Anell, 2018.
"Can pay‐for‐performance to primary care providers stimulate appropriate use of antibiotics?,"
Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 39-54, January.
- Anell, Anders & Dietrichson, Jens & Ellegård, Lina Maria, 2015. "Can Pay-for-Performance to Primary Care Providers Stimulate Appropriate Use of Antibiotics?," Working Papers 2015:36, Lund University, Department of Economics, revised 29 Jun 2016.
- Eswaran, Mukesh & Gallini, Nancy, 2016. "Rescuing the Golden Age of Antibiotics: Can Economics Help Avert the Looming Crisis?," Economics working papers nancy_gallini-2016-9, Vancouver School of Economics, revised 04 Jul 2016.
- David H. Howard, 2004. "Resistance‐induced antibiotic substitution," Health Economics, John Wiley & Sons, Ltd., vol. 13(6), pages 585-595, June.
- Smith, Richard D. & Coast, Joanna, 1998. "Controlling antimicrobial resistance: a proposed transferable permit market," Health Policy, Elsevier, vol. 43(3), pages 219-232, March.
- Bente Halvorsen & Tiril Willumsen, 2004. "Willingness to pay for dental fear treatment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(4), pages 299-308, November.
- Bethany Cooper & Walter O. Okello, 2021. "An economic lens to understanding antimicrobial resistance: disruptive cases to livestock and wastewater management in Australia," Australian Journal of Agricultural and Resource Economics, Australian Agricultural and Resource Economics Society, vol. 65(4), pages 900-917, October.
- Yoel Lubell & Thomas Althaus & Stuart D Blacksell & Daniel H Paris & Mayfong Mayxay & Wirichada Pan-Ngum & Lisa J White & Nicholas P J Day & Paul N Newton, 2016. "Modelling the Impact and Cost-Effectiveness of Biomarker Tests as Compared with Pathogen-Specific Diagnostics in the Management of Undifferentiated Fever in Remote Tropical Settings," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-13, March.
- Barlow, Euan & Morton, Alec & Megiddo, Itamar & Colson, Abigail, 2022. "Optimal subscription models to pay for antibiotics," Social Science & Medicine, Elsevier, vol. 298(C).
- Eswaran, Mukesh & Gallini, Nancy, 2017.
"Can Competition Extend the Golden Age of Antibiotics?,"
Microeconomics.ca working papers
-2017-9, Vancouver School of Economics, revised 19 Oct 2017.
- Eswaran, Mukesh & Gallini, Nancy, 2018. "Can Competition Extend the Golden Age of Antibiotics?," Microeconomics.ca working papers tina_marandola-2018-1, Vancouver School of Economics, revised 29 Jan 2018.
- John B. Horowitz & H. Brian Moehring, 2004. "How property rights and patents affect antibiotic resistance," Health Economics, John Wiley & Sons, Ltd., vol. 13(6), pages 575-583, June.
- Simon Pol & Danielle E. M. C. Jansen & Alike W. Velden & Christopher C. Butler & Theo J. M. Verheij & Alex W. Friedrich & Maarten J. Postma & Antoinette D. I. Asselt, 2022. "The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance," PharmacoEconomics, Springer, vol. 40(8), pages 823-833, August.
- Elamin H. Elbasha, 2003. "Deadweight loss of bacterial resistance due to overtreatment," Health Economics, John Wiley & Sons, Ltd., vol. 12(2), pages 125-138, February.
- Antonio Giuffrida & Hugh Gravelle, 1998. "Paying patients to comply: an economic analysis," Health Economics, John Wiley & Sons, Ltd., vol. 7(7), pages 569-579, November.
- Joanna Coast & Richard Smith & Anne‐Marie Karcher & Paula Wilton & Michael Millar, 2002. "Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance?," Health Economics, John Wiley & Sons, Ltd., vol. 11(7), pages 637-647, October.
- Catherine A. Goodman & Paul G. Coleman & Anne J. Mills, 2001. "Changing the first line drug for malaria treatment—cost‐effectiveness analysis with highly uncertain inter‐temporal trade‐offs," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 731-749, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:hlthec:v:5:y:1996:i:3:p:217-226. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www3.interscience.wiley.com/cgi-bin/jhome/5749 .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.